SpeechPathology.com Phone: 800-242-5183


EDU Healthcare Opportunities

ADHD and Kids: What is going on?

ADHD and Kids: What is going on?
Max S. Chartrand, PhD
September 8, 2003
Share:

Editor's note: Although we don't usually publish ''op-ed'' material, this article presents compelling and important information, and I believe it is beneficial for all of us who work with, have, or were once were children! Please send your thoughts to me on this topic. We'll consider all responsible opinions for publication. Thanks! ---Douglas Beck, Editor-In-Chief.
Introduction:

With school starting again, I'd like to address a serious health issue that has been a long-standing interest of mine. This fall, more than 7 million American school-aged children1,2, or about 1 in 12, will be placed on a stimulant, similar to ''speed.'' Ritalin or its chemical variants are used to treat Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a non-clinical condition that many of us in the cognitive/communicative research community consider to be a somewhat contrived epidemic.

Just 20 years ago there were less than a half-million children placed on these powerful and potentially dangerous drugs. But between 1990 to 1997 there has been a 700% increase in the use of Ritalin et al3, and the rate continues today unabated. The United States, with only 5% of the world's population, consumes more than 85% of such medications4.To me, this state of affairs appears out of control!

Perhaps at the heart of this ''epidemic'' is the alliance between the U. S. Department of Education (DOE) and certain pharmaceutical companies5. It appears that billions of federal taxpayer dollars are dangled in front of cash-starved public schools, complete with slick video tape and print materials and workshops, to help the schools find, identify and treat as many children as possible. So aggressive has been the campaign to force this form of treatment and non-clinical diagnosis on parents and the public school system, that already 13 states have passed laws forbidding its recommendation.

In the meantime, more and more, medical doctors who previously resisted doing so have begun ''diagnosing'' without benefit of clinical tests or identifiable physical markers, and giving out prescriptions for powerful drugs like Ritalin, Wellbutrin, Effexor, and Desipramine. These are Class II narcotics ranked with opium, cocaine, morphine, and codeine6. Side effects can include; anxiety (for which anti-anxiety medication is often given), insomnia (sleeping pills for this), kidney failure, enlarged heart, seizures, addictive personality, and even death7.


Max S. Chartrand, PhD



Related Courses

Treatment Approach Considerations for School-Aged Children with Speech Sound Disorders
Presented by Kathryn Cabbage, PhD, CCC-SLP
Video
Course: #9472Level: Intermediate1 Hour
This course will address the theoretical underpinnings and research base related to differential diagnosis and treatment of articulation and phonological deficits in children with speech sound disorders. Special considerations for how to tailor evaluation and intervention to meet the needs of school-age children will be discussed.

The Ripple Effect of Stuttering: A Community-Based Approach
Presented by Craig Coleman, MA, CCC-SLP, BCS-F, ASHA Fellow, Mary Weidner, PhD, CCC-SLP
Video
Course: #9217Level: Intermediate2 Hours
This is Part 2 of a four-part series. The stuttering experience has a ripple effect that extends far beyond the child who stutters. Parents, teachers, peers, and others must possess both knowledge and skills to best support children who stutter. This course will highlight new clinical tools and resources to provide a community-based treatment approach for stuttering. (Part 1 - Course 9278, Part 3 - Course 9301, Part 4 - Course 9304)

Behavioral Frameworks for Dementia Management
Presented by Mary Beth Mason, PhD, CCC-SLP, Robert W. Serianni, MS, CCC-SLP, FNAP
Video
Course: #9473Level: Intermediate1 Hour
This course will focus on cognitive-communication intervention strategies for various dementia presentations and will provide a review of evidence-based treatment. Behavioral frameworks along with their rationales will be introduced and applied across several dementia types and mild, moderate and severe levels of impairment.

20Q: Infection Control Strategies for SLPs
Presented by A.U. Bankaitis Smith, PhD
Text
Course: #9729Level: Intermediate1 Hour
Speech-language pathologists are expected by policy authorities to apply appropriate measures to protect patients, co-workers and themselves in clinical situations that may expose individuals to infectious microbes. This article provides practical guidelines for implementing infection control principles within the context of the COVID-19 pandemic, including discussion of personal protective equipment (PPE) and disinfecting and cleaning products.

Thickened Liquids in Clinical Practice: The Plot “Thickens”
Presented by Angela Mansolillo, MA, CCC-SLP, BCS-S
Video
Course: #10497Level: Intermediate1 Hour
Clinicians who utilize thickened liquids in their clinical practice are aware of their benefits, but what about the risks and contraindications? Advantages and disadvantages of thickened liquids are reviewed in this course with a focus on clinical outcomes, including impacts on medication administration, lung health, and hydration. Product types are evaluated to facilitate appropriate choices for individual clients.

Our site uses cookies to improve your experience. By using our site, you agree to our Privacy Policy.